Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Jump 11.0% to Record 240.1 Billion Yen in 2013: Boehringer Japan
April 24, 2014
- Astellas Aims to Dominate SGLT-2 Inhibitor Market with Suglat
April 23, 2014
- Lilly Japan Starts PIII Study of Tadalafil for DMD Treatment
April 22, 2014
- Metal Objects Found in Voltaren Suppositories in Aichi Pref.: Novartis
April 22, 2014
- Nihon Generic Obtains Teva’s Manufacturing Plant, Eyeing Expansion of Production Capacity
April 22, 2014
- Entry into Japan Biosimilar Market Will Take Time, Says BI Chairman
April 21, 2014
- PIII Trial of Asthma Drug Benralizumab Kicks Off in Japan: Kyowa Kirin
April 21, 2014
- NBI Postpones Launch of Anticancer Drug Giotrif until May 7
April 21, 2014
- Kyowa Kirin, Amgen of US Terminate License Agreement for Mogamulizumab
April 21, 2014
- Astellas Launches Japan’s 1st SGLT-2 Inhibitor Suglat
April 18, 2014
- Sanofi Aims to Top SGLT-2 Inhibitor Market with Apleway
April 18, 2014
- “MRs’ Manners” Are Opening Theme in Panel Discussion Held by MREAC
April 18, 2014
- Sales of Diovan Fell 22% in 3rd Quarter of FY2013; Overall Growth of ARB Market Could Fall Short of Expectations
April 18, 2014
- Boehringer Ingelheim Reports 14.1% Increase in Operating Profit to 2,114 Million Euro in 2013
April 17, 2014
- Metal Found in Voltaren Product Again: Novartis
April 17, 2014
- AZ Offers Sales Rep Jobs to over 100 New Graduates in FY2014
April 16, 2014
- Eisai President Naito Awarded Honorary KBE
April 16, 2014
- FY2015 Recruitment Plan: Eisai to Resume Offering Jobs to New Graduates
April 15, 2014
- Novartis Pharma Notified Police about Metal Object Found in Voltaren Product
April 15, 2014
- Hisamitsu Total Sales Up 5.5% but Domestic Ethical Drug Sales Down 1.8%
April 14, 2014
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…